Abstract
Artemisinin, isolated from the traditional Chinese medicinal plant qīng hāo 青蒿 (Artemisia annua) and its derivatives are used for treatment of malaria. With treatment failures now being recorded for the derivatives and companion drugs used in artemisinin combination therapies new drug combinations are urgently required. The amino-artemisinins artemiside and artemisone display optimal efficacies in vitro against asexual and sexual blood stages of the malaria parasite Plasmodium falciparum and are active against tumour cell lines. In continuing the evolution of combinations of the amino-artemisinins with new drugs, we examine the triterpenoid quinone methide celastrol isolated from the traditional Chinese medicinal plant léi gōng téng 雷公藤 (Tripterygium wilfordii). This compound is redox active, and has attracted considerable attention because of potent biological activities against manifold targets. We report that celastrol displays good IC50 activities ranging from 0.50–0.82 µM against drug-sensitive and resistant asexual blood stage Pf, and 1.16 and 0.28 µM respectively against immature and late stage Pf NF54 gametocytes. The combinations of celastrol with each of artemisone and methylene blue against asexual blood stage Pf are additive. Given that celastrol displays promising antitumour properties, we examined its activities alone and in combinations with amino-artemisinins against human liver HepG2 and other cell lines. IC50 values of the amino-artemisinins and celastrol against HepG2 cancer cells ranged from 0.55–0.94 µM. Whereas the amino-artemisinins displayed notable selectivities (SI > 171) with respect to normal human hepatocytes, in contrast, celastrol displayed no selectivity (SI < 1). The combinations of celastrol with artemiside or artemisone against HepG2 cells are synergistic. Given the promise of celastrol, judiciously designed formulations or structural modifications are recommended for mitigating its toxicity.
1 Introduction
Treatment of malaria with artemisinin combination therapies (ACTs) comprising artemisinin or one of its clinical derivatives (Figure 1) (; Li et al., 2017) with a longer half-life antimalarial drug (; Wells et al., 2009; World Health Organisation, 2021) is compromised by enhanced tolerance of the malaria parasite, principally Plasmodium falciparum (Pf), to the artemisinin, and resistance to the partner drug (Phyo and von Seidlein, 2017; Woodrow and White, 2017; Ouji et al., 2018; Mairet-Khedim et al., 2021). The increased tolerance to artemisinins is due to induction of dormancy (quiescence) in ring stage parasites in response to drug pressure. Whilst various explanations are put forward for quiescence (Mbengue et al., 2015; Siriwardana et al., 2016), the most likely cause is an enhanced stress response (; Rocamora et al., 2018; Wellems et al., 2020). New drug combinations based on rational consideration of mechanism of action of the components are urgently required. Here we focus on amino-artemisinins () that have enhanced efficacies against all blood stages of the malaria parasite. The best-known is artemisone (Figure 1) (; Vivas et al., 2007). Its potent biological activities are ascribed to the properties of the amino group at C-10 (Wu et al., 2016), improved pharmacokinetics (Nagelschmitz et al., 2008), and generation of active metabolites with relatively long half-lives (Schmeer et al., 2005; Nagelschmitz et al., 2008; ; Watson et al., 2021).
FIGURE 1
In order to select the combination partner, one needs to briefly consider mechanism of action (MoA) of artemisinins. Whilst the thesis involving artemisinin activation by heme is the most strongly supported (; Quadros et al., 2022), there are difficulties in reconciling this with experimental observations, known aspects of free radical chemistry, and in particular structure-activity relationships of artemisinin derivatives and analogues (; ). We have shown that these compounds rapidly oxidize reduced flavin cofactors of the disulfide reductases glutathione reductase (GR), thioredoxin reductase (TrXR) and others important for maintaining redox homeostasis in the malaria parasite. The artemisinin is thereby irreversibly reduced and enhancement of oxidative stress ensues (Figure 2) (; ; ).
FIGURE 2
In order to enhance the stress response, a drug capable of redox cycling is best used in combination with the artemisinin. One such is methylene blue (MB) (Figure 3), active against asexual blood stage malaria parasites and displaying synergism with artemisinins (; ). MB also has gametocytocidal activity () that is synergized by artemiside and artemisone (; Wong et al., 2019). Notably, MB rapidly oxidizes the same reduced flavin cofactors that are oxidized by the artemisinins and is thereby reduced to leucomethylene blue (LMB). The latter is reoxidized by oxygen to MB and the ensuing redox cycling results in build-up of ROS. Thus, NADPH that regenerates FADH2 from FAD undergoes futile consumption (Figure 3) (). The redox cycling of MB will promote the action of artemisinins (Figure 3).
FIGURE 3
Artemisinins also show antitumour activities (; Konstat-Korzenny et al., 2018; ; ; Mancuso et al., 2021). Artemisone elicits activities superior to artemisinin in vitro (; ). The activities (IC50) against tumour cell lines range from 0.26–95.7 µM (; ; ; Wu et al., 2018; Wong et al., 2020). As in the case of malaria, MoA likely involves interruption of function of flavin cofactors of disulfide reductases, leading to generation of intracellular ROS that through downstream signalling events overwhelms redox homeostasis in the cancer cell (; Wong et al., 2020). Other ROS-independent pathways may also be involved (Qin et al., 2015; ). Combinations of artemisinins with known and experimental cancer drugs have been examined (; Kumar et al., 2019; ). Artemisone shows additivity in combinations with oxaliplatin and gemcitabine in vitro (). Artemisone is also active against A375 melanoma cells (IC50 95.7 µM), wherein synergism with the redox-active copper (II) complex of the anticancer drug elesclomol is observed. Further, generation of ROS is demonstrated, and use of flow cytometry in combination with the FITC Annexin V assay indicates the artemisinin induces apoptotic cell death, that is greatly enhanced in the presence of the companion drug (Wong et al., 2020). Thus, the case for continuing the examination of combinations of the amino-artemisinins with redox-active drugs to enhance cancer chemotherapy is clear.
We now consider the lipophilic triterpenoid quinone-methide celastrol (Figure 4), also known as tripterine, isolated from the traditional Chinese medicinal plant léi gōng téng 雷公藤 or Thunder of God vine (Tripterygium wilfordii) as the redox component (). Celastrol exhibits potent antitumour and other biological activities that involve inter alia redox activity associated with generation of intracellular ROS and modulation of downstream signalling pathways (Moreira et al., 2019; Peng et al., 2019; ; Lu et al., 2021; Youns et al., 2021). Celastrol also inhibits the flavoenzyme siderophore A that catalyzes the hydroxylation of L-ornithine in Apergillis fumigatus. Whilst in silico experiments suggested reversible binding at the active site of siderophore A (Martín Del Campo et al., 2016), the effect of celastrol on the redox cycling of the flavin cofactor (cf. Effect of MB, Figure 3) was not considered. However, that quinone-methides are redox active and rapidly oxidize reduced flavin cofactors in flavoenzymes is illustrated by the behaviour of the quinone oxidoreductases NQO1 and NQO2 upon treatment with o- and p-quinone methides derived from o- and p-cresol respectively (Kucera et al., 2013). Thus, we anticipate as for MB (Figure 3) (; Wong et al., 2019), celastrol should synergize the action of artemisinins against different targets. However, although celastrol is a biologically potent compound, it displays untoward toxicity associated with numerous off-target effects. Thus, considerable effort has been directed towards development of controlled-release formulations of celastrol (; Shi et al., 2020; ; Wagh et al., 2021) or preparation of less toxic derivatives largely associated with conversion of the carboxylic acid to amide derivatives (; ; ).
FIGURE 4
Antimalarial activities of celastrol and its naturally-occurring methyl ester pristimerin (Figure 4) have been reported (; Li et al., 2019); for celastrol, IC50 activities against the chloroquine sensitive Pf NF54 strain and multidrug resistant Pf K1 strain are 564 and 401 nM respectively, with similar values for pristimerin (IC50 NF54 583 nM, K1 409 nM). Thus far, the antimalarial MoA has not been elucidated. However, it is clear that the redox-active quinone methide moiety of celastrol bestows overall biological activity (Kucera et al., 2013; Moreira et al., 2019; Peng et al., 2019; ; Lu et al., 2021; Youns et al., 2021). In this sense, this aspect correlates with the antimalarial activities of MB and redox-active naphthoquinones such as menadione (Lanfranchi et al., 2012; ) that are active against asexual and sexual blood stage parasites (; Tanaka et al., 2015; ; Sidorov et al., 2016; ).
Here, we present the results of an evaluation of the antimalarial activity in vitro of celastrol alone and in combination with each of artemisone and MB using standardized screens (; Wong et al., 2019). Likewise, antitumour activities of each of artemiside, artemisone and celastrol individually and in combination against selected cancer cell lines according to reported methods are described (Wong et al., 2020; Ng et al., 2022).
2 Materials and methods
2.1 Materials
Reference compounds and the artemisinins used for screening were ≥95% pure (; Wong et al., 2019; ). Celastrol purchased from the Chengdu SanHerb BioScience company (Chengdu, China), was ≥95% pure, and was used without further purification.
2.2 Antimalarial efficacies
2.2.1 Antimalarial efficacies
In vitro cultivation of asexual and gametocyte P. falciparum parasites: P. falciparum asexual blood stage parasites were cultivated in human erythrocytes in RPMI-1640 media supplemented with AlbuMax II under sterile conditions and in a hypoxic environment (90% N2, 5% CO2, and 5% O2) at 37°C as described previously (; Wong et al., 2019). Gametocytes were produced from asexual blood stage parasites in a stage-specific manner through induction of cellular stress as described previously (Reader et al., 2015; ; Wong et al., 2019; Reader et al., 2022).
2.2.2 Asexual blood stage parasites
DHA, artesunate, artemether, chloroquine (CQ), and methylene blue (MB) were used as reference drugs. All assay conditions are as previously described (; Wong et al., 2019). Compound working solutions were prepared from a 10 mM stock solution in 100% (v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich) in AlbuMAX II supplemented RPMI 1640 medium with a final DMSO concentration of 0.1% (v/v), shown to be nontoxic to be nontoxic to intraerythrocytic asexual blood stage parasites (). Dose-responses were determined using a 2-fold serial drug dilution on in vitro 95% ring-stage intraerythrocytic Pf parasites (1% parasitemia, 1% hematocrit) at 37°C under 90% N2, 5% CO2, and 5% O2 atmospheric conditions, detecting SYBR green I fluorescence as a marker for parasite proliferation following a 96 h drug treatment (Smilkstein et al., 2004; Verlinden et al., 2011). Activity against the Pf drug-sensitive NF54 strain and the multi drug-resistant K1 (resistant to CQ, quinine, pyrimethamine, and cycloguanil), and W2 (resistant to CQ, quinine, pyrimethamine, and cycloguanil) strains was evaluated. Untreated and 1 µM CQ-treated parasites were included as positive and negative controls. MB and artemisone were included as internal reference standards. Data analysis was performed using GraphPad Prism (version 6) software, intra-assay variability was monitored with Z-factors, and acceptable inter-assay reproducibility was determined from the percent coefficient of variation (CV) (Reader et al., 2015). Data are from technical triplicates, performed for three biological replicates. Results are expressed as the compound concentration at which 50% parasite viability/proliferation is affected (IC50).
2.2.3 Immature and late-stage gametocytes
Gametocytocidal activity was determined using the transgenic NF54-Pfs16-GFP-Luc reporter lines (; Reader et al., 2015; Reader et al., 2022) to derive dose responses and determine IC50 after 48 h continuous drug pressure against immature gametocytes (2-fold serial drug dilutions on ≥95% stage II-III gametocytes) or after both 48 and 72 h continuous drug pressure against more mature late-stage IV - V gametocytes (≥90% stages IV and V, 10-fold serial drug dilutions) (2%–3% gametocytemia, 2% hematocrit) at 37°C under hypoxic conditions. Untreated and 5 μM MB-treated immature and late-stage gametocytes were included as positive and negative controls. MB and artemisone were included as internal reference standards. In all cases, an interference assay to eliminate false positives from possible compound interference with the luciferase readout was run in parallel. Unless otherwise indicated, data are from technical triplicates, performed for three biological replicates. Complete dose-response curves are given in the (Supplementary Figures S2A,B).
2.2.4 Drug combination assays against asexual blood stage parasites
The in vitro interactions of celastrol with artemisone and MB was determined using a fixed-ratio isobole analysis on Pf NF54 asexual parasites (SYBR Green I-based fluorescence). Briefly, the drugs were applied alone at their respective IC50 value and in fixed-drug percentage combination ratios of IC50 values of 100:0, 80:20, 60:40, 40:60, 20:80, and 0:100, two-fold serially diluted and grown for 96 h at 37°C under the 90% N2, 5% O2, and 5% CO2 gas mixture in 96-well plates to obtain the IC50 dose response curves for each drug alone and in the fixed-drug ratio (Ohrt et al., 2002; ). The fractional inhibitory concentration (FIC) for each drug in the combination was calculated as follows:
FIC = IC50 of drug A in combination with drug B/IC50 of drug A
The paired FIC values for the drugs in each combination were linearly plotted to provide the isobologram. The ΣFIC of FIC of drug A in combination with FIC of drug B was determined by calculating the mean FIC value, to obtain the representative FIC value for the drug combination. Data obtained were analysed in Excel, and sigmoidal dose-response curves and isobolograms were plotted using GraphPad 6.0. Experiments were performed in triplicate, and repeated 3 times.
2.3 Cytotoxicity
Proliferative and non-proliferative mammalian cell lines: human liver and lung cancer cell lines HepG2 and A549, and immortalized normal liver LO2 and lung BEAS-2B cells were purchased from ATCC (Manassas, VA, United States). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics penicillin (50 U/mL) and streptomycin (50 μg/ml; Invitrogen, United Kingdom). All cells were incubated at 37°C in a 5% humidified CO2 incubator.
2.3.1 Assays
All test compounds were dissolved in DMSO at a final concentration of 50 mM and stored at −20°C before use. Cytotoxicity was assessed with A549, HepG2, BEAS-2B and LO2 cells. The MTT assay with 3-(4,5-dimethylthiazole-2yl)-2,5-diphenyltetrazolium bromide (5 mg/ml) was performed as previously described (Ng et al., 2022). Briefly, 4 × 103 cells per well were seeded in 96-well plates before drug treatment. After overnight cell culture, the cells were exposed to different concentrations of selected compounds (0.19–100 μM) for 72 h. Cells without drug treatment were used as control. Next, 10 μl of the MTT solution was added to each well and incubated at 37°C for another 4 h. Solubilization buffer (100 μl) was then added (10 mM HCl in a solution of 10% of SDS) and incubated overnight. The absorbance A at 570 nm was measured on the next day. The percentage of cell viability was calculated using the following formula: Cell viability (%) = Atreated/Acontrol × 100. Dose response curves for all assays are given in the Supplementary Figures S3–S6.
2.3.2 Drug combination assays
For the drug combination inhibitory assays, six drug preparations, of which four comprised combinations of either artemiside or artemisone with celastrol in a fixed ratio of 80:20, 60:40, 40:60, and 20:80 were prepared and screened against HepG2 liver hepatocellular carcinoma and LO2 human normal hepatocytes respectively. Two of these six preparations employed each of artemiside, artemisone or celastrol alone at a concentration approximately 5–7 times higher than the IC50 of the individual drug as presented in Table 4. For artemiside, 500 µM was taken as 5-fold IC50 and for celastrol 20 µM was taken as 7-fold IC50. Thus, six combinations for artemiside (µM) and celastrol (µM) prepared were 500:0, 400:4, 300:8, 200:12, 100:16, and 0:20, respectively.
As above for the malaria combination assays, a mean ΣFIC<1.0 represents a synergistic interaction, >1.3 represents an antagonistic interaction and ΣFIC = 1 represents an indifferent or additive interaction. Additivity, synergism and antagonism were also be established from the linear plots constructed from the FIC values of each of the drugs. A concave hyperbolic plot indicates synergism, a convex hyperbolic plot indicates an antagonistic interaction, and a straight line indicates an additive interaction. Isobole analysis of the combinations of each of artemiside and artemisone in combination with celastrol was performed against HepG2 and LO2 cells respectively. In Figure 5 is presented the isoboles for each drug combination.
FIGURE 5
3 Results and discussion
3.1 Antimalarial efficacy
3.1.1 Asexual blood stage parasites
Activity was determined using the SYBR Green I based fluorescence assay on asexual blood stages of the NF54 (drug sensitive), K1 and W2 (drug resistant) strains of P. falciparum. In Table 1 are presented the activities and the resistance index (RI) for each drug resistant strain. Dose response curves are given in the Supplementary Figures S1A–C. Also included in Table 1 for direct comparison of activities against celastrol are data for the internal reference standards MB and artemisone recorded at the same time as for celastrol. The activities correlate with the data previously reported for these compounds including the other artemisinin derivatives of Table 1 (; Wong et al., 2019).
TABLE 1
| aCompound | IC50 nMb | ||||
|---|---|---|---|---|---|
| NF54 | K1 | RIc | W2 | RId | |
| Methylene Bluef | 5.9 ± 0.8e/5.0 ± 0.8f | 6.45 ± 0.30f | 1.29f | 5.13 ± 0.31f | 1.03f |
| DHAf | 2.51 ± 0.19 | 1.51 ± 0.33 | 0.6 | 1.74 ± 0.22 | 0.7 |
| Artemetherf | 1.86 ± 0.17 | 9 ± 2 | 4.8 | 7 ± 1 | 3.8 |
| Artesunatef | 3.00 ± 0.29 | 4 ± 1 | 1.3 | 2.4 ± 0.4 | 0.8 |
| Celastrol | 820 ± 190 | 700 ± 100 | 0.85 | 500 ± 100 | 0.61 |
| Artemisidef | 1.11 ± 0.17 | 1.6 ± 0.4 | 1.47 | 1.75 ± 0.27 | 1.58 |
| Artemisonef | 2.32 ± 0.76e/1.2 ± 0.4f | 1.01 ± 0.19f | 0.85f | 1.6 ± 0.4f | 1.36f |
Activities (nM) in vitro against asexual blood stage P. falciparum.
Structures of artemisinins in Figure 1, of celastrol in Figure 4; P. falciparum NF54 CQ, sensitive; K1: CQ, pyrimethamine, mefloquine, cycloguanil resistant; W2: CQ, quinine, pyrimethamine, cycloguanil resistant
Results for proliferative (SYBR, Green I) assays from three biological replicates, each performed as technical triplicates, mean ± SEM
Resistance index (RI) = IC50 K1/IC50 NF54
IC50 W2/IC50 NF54
data for internal reference standards, this study
data from ; Wong et al., 2019.
Interestingly, celastrol displays antimalarial activities somewhat similar to those previously recorded (IC50Pf NF54 564 nM, Pf K1 401 nM) using the tritiated hypoxanthine assay (Li et al., 2019), confirming that activities of celastrol are orders of magnitude inferior to those of the artemisinins. Whilst the activities in terms of IC50 data are better than those of the naphthoquinone menadione recorded using the tritiated hypoxanthine assay (IC50 9.6–12 µM) (Lanfranchi et al., 2012), there are more recent examples of redox active naphthoquinones displaying superior activities against asexual blood stages of drug-sensitive and -resistant Pf (Verlinden et al., 2011; ; Sidorov et al., 2016; ; Ng et al., 2022).
3.1.2 Stage specific gametocyte activity
Stage-specific activities of celastrol against immature (stage II-III) and late stage (stage IV-V) gametocytes were determined with the luc reporter line as described previously (; Wong et al., 2019). Data are presented in Table 2. Also included in Table 2 for direct comparison of activities with celastrol are gametocytocidal data for MB, artemisone and the artemisinin derivatives recorded previously (; Wong et al., 2019). Dose response curves are presented in the Supplementary Figures S2A,B. Although celastrol displayed relatively mediocre activity against immature stage gametocytes, it showed good activity against late stage IV-V gametocytes. This approximately 4-fold greater activity against late stage gametocytes is noteworthy, and in this respect, is more active than or equipotent with naphthoquinones against this stage for which comparable data have been obtained, such as for plasmodione (IC50 1,107 nM) () and a series of imidazolo-naphthoquinones (IC50 164–1,088 nM) ().
TABLE 2
| aCompound | bImmature stage II-III (luc 48 h) IC50 nM | cLate stage IV-V (luc 72 h) IC50 nM | Fold change preference ratio EG to LG | Fold change preference ratio LG to EG |
|---|---|---|---|---|
| Methylene Blued | 95.0 ± 11.3 | 143.0 ± 16.7 | 1.5 | 0.7 |
| DHAd | 43.0 ± 3.9 | 33.66 ± 1.98 | 0.78 | 1.3 |
| Artemetherd | 37.7 ± 2.0 | 136.2 ± 85.9 | 3.6 | 0.28 |
| Artesunated | 62.8 ± 3.0 | 259.4 ± 80 | 4.1 | 0.24 |
| Celastrol | 1,160 ± 66.5 | 282.4 ± 96.2 | 0.2 | 4.1 |
| Artemisided | 16.4 ± 1.0 | 1.5 ± 0.5 | 0.09 | 10.9 |
| Artemisoned | 1.94 ± 0.11 | 42.4 ± 3.3 | 21.9 | 0.05 |
Activities (nM) in vitro against immature stage II-III and late stage IV-V P. falciparum NF54 gametocytes.
immature stage II-III, gametoctyes (>90%)
late stage IV-V, gametocytes (>90%) determined using the luciferase based assay against the Luc reporter cell line; results are representative of three biological replicates (n = 3), each performed in technical triplicates, mean ± SEM; data are from 48 h for immature gametocytes and 72 h for late stage IV-V, gametocytes drug incubation period
data from , Wong et al., 2019.
3.1.3 Antimalarial drug combination studies
As previously recorded for each of artemiside and artemisone in combination with MB (), drug-drug interactions were monitored through evaluation of fractional inhibitory concentration (FIC) as determined by isobolograms. A mean ΣFIC<1.0 represents a synergistic interaction, >1.3 an antagonistic interaction and ΣFIC = 1 an indifferent or additive interaction. Isobologram analysis of the combinations of each of artemisone and MB in combination with celastrol was performed against the asexual stages of Pf NF54 using the SYBR Green I based assay. In Table 3 are shown the calculated FIC values for the independent combinations at each ratio as well as the ∑FIC values for each combination. In Figure 5 are presented the independent isoboles for each drug combination.
TABLE 3
| Drug ratio | FIC values | |||||
|---|---|---|---|---|---|---|
| Artemisone | Celastrol | ΣFIC | MB | Celastrol | ΣFIC | |
| 80:20 | 0.69 | 0.50 | 1.19 | 0.79 | 0.41 | 1.06 |
| 60:40 | 0.39 | 0.60 | 0.99 | 0.66 | 0.72 | 1.39 |
| 40:60 | 0.24 | 0.76 | 1.00 | 0.67 | 1.02 | 1.73 |
| 20:80 | 0.12 | 0.93 | 1.06 | 0.70 | 0.81 | 0.81 |
| Avg ΣFIC | 1.06 | 1.25 | ||||
FIC values for artemisone and MB in combination with celastrol against asexual blood stage Pf NF54.a
Calculated FIC, and ΣFIC (highlighted in bold) values following isobole analysis of each of artemisone and methylene blue MB, in combination with celastrol. Results are representative of four independent biological repeats (n = 4), each performed as technical triplicates, ± SEM.
The combination of each of artemisone and MB with celastrol showed additive interactions as is apparent from the isobolograms (Figure 5) as well as the ΣFIC values for these combinations, with an average ΣFIC of 1.06 (95% confidence interval (CI) 94.91–95.09) for artemisone with celastrol and an average ΣFIC of 1.25 (95% CI 94.61–95.39) for MB with celastrol, similar to that previously observed for artemisone and MB (ΣFIC of 1.14) on asexual blood stage parasites ().
3.2 Antitumor activities
Cytotoxicity was assessed for each of artemisinin, DHA and artemether, and the amino-artemisinins artemiside and artemisone, and celastrol against A549 human lung carcinoma, BEAS-2B non-tumorigenic human bronchial epithelium, HepG2 liver hepatocellular carcinoma and LO2 human normal hepatocytes using the MTT assay (Ng et al., 2022). Data are presented in Table 4, and dose response curves are given in the Supplementary Figures S3–S6.
TABLE 4
| aCompound | IC50 µMb | |||||
|---|---|---|---|---|---|---|
| A549 | BEAS-2B | cSI | HepG2 | LO2 | cSI | |
| Artemisinin | >100 | >100 | — | >100 | >100 | — |
| DHA | 62.6 ± 3.4 | 21.2 ± 1.4 | 0.3 | >100 | 30.7 ± 2.2 | <0.3 |
| Artemether | >100 | >100 | — | 1.02 ± 0.2 | >100 | >98 |
| Artemiside | >100 | 32.1 ± 2.7 | <0.3 | 0.55 ± 0.02 | >100 | >183 |
| Artemisone | >100 | 73.6 ± 1.4 | <0.7 | 0.58 ± 0.2 | >100 | >171 |
| Celastrol | 2.83 ± 0.12 | 0.45 ± 0.1 | 0.16 | 0.94 ± 0.1 | 0.78 ± 0.2 | 0.83 |
Cytotoxicities of artemisinins and celastrol (µM) against tumour and non-proliferating cell lines in vitro.
A549 human lung carcinoma; BEAS-2B, non-tumorigenic human bronchial epithelium; HepG2 liver hepatocellular carcinoma; LO2 human normal hepatocyte; results are reported as inhibitory concentrations IC50 from three independent biological replicates, each performed as technical replicates ±standard deviation (SD).
SI, selectivity index IC50 normal cell line/IC50 tumour cell line.
The standout features are the relative toxicity of DHA towards the normal cell lines (SI < 1), and the selective activities of artemiside and artemisone against liver hepatocellular carcinoma cell lines (SI > 183 and >171 respectively), compared with celastrol which displays no selectivity with respect to normal hepatocytes (SI < 1, Table 4) ().
Next, combinations of each of artemiside and artemisone with celastrol were examined, according to the method used to establish additivity/synergism described above. Interestingly, the mean of ΣFIC<1.0 for assays against HepG2 carcinoma cell lines indicates each of artemiside and artemisone display synergism with celastrol. Against the normal hepatocyte LO2 cell line, whilst the interaction of artemisone with celastrol was synergistic, that of artemiside was additive. Synergism and additivity were also evident from the linear plots determined from the FIC values of each of the drugs (Table 5 and Figure 6). Thus, synergism is confirmed for combinations of the amino-artemisinins with celastrol against the HepG2 carcinoma cell line, and for artemisone-celastrol against human normal hepatocyte LO2.
TABLE 5
| Cell line | Drug ratio | FIC values | |||||
|---|---|---|---|---|---|---|---|
| Artemiside | Celastrol | ΣFIC | Artemisone | Celastrol | ΣFIC | ||
| HepG2 | 80:20 | 0.57 | 0.08 | 0.65 | 0.76 | 0.14 | 0.90 |
| 60:40 | 0.4 | 0.14 | 0.54 | 0.48 | 0.23 | 0.71 | |
| 40:60 | 0.42 | 0.34 | 0.76 | 0.36 | 0.4 | 0.76 | |
| 20:80 | 0.16 | 0.35 | 0.51 | 0.3 | 0.88 | 1.18 | |
| Avg ΣFIC | 0.61 | 0.89 | |||||
| LO2 | 80:20 | 0.59 | 0.48 | 1.07 | 0.99 | 0.23 | 1.22 |
| 60:40 | 0.45 | 1.03 | 1.48 | 0.47 | 0.29 | 0.76 | |
| 40:60 | 0.33 | 1.56 | 1.89 | 0.28 | 0.4 | 0.68 | |
| 20:80 | 0.09 | 1.2 | 1.29 | 0.18 | 0.7 | 0.88 | |
| Avg ΣFIC | 1.43 | 0.88 | |||||
Cytotoxicity FIC values for artemiside and artemisone in combination with celastrol.a
Calculated FIC, and ΣFIC (highlighted in grey) values following isobole analysis of each of artemiside and artemisone in combination with celastrol. Results are representative of four independent biological repeats (n = 4), each performed as technical triplicates, ± SEM; HepG2 liver hepatocellular carcinoma, LO2 human normal hepatocytes.
FIGURE 6
4 Conclusion
The activities of the oxidant amino-artemisinins artemiside and artemisone as well as the redox active drug celastrol were determined against P. falciparum blood-stage asexual drug sensitive NF54 and multidrug resistant K1 and W2 parasite strains. It is demonstrated that the combinations of each of artemisone and of MB with celastrol are additive, with a final ΣFIC of 1.06 for artemisone with celastrol and a final ΣFIC of 1.25 for MB with celastrol. Therefore, for the asexual blood stage parasites, the results for the artemisone-celastrol combination are similar to the artemisone-MB combinations recorded earlier, wherein an ΣFIC of 1.14 is observed (). With respect to the oxidant mode of action of the artemisinin, this thus strongly supports the precept of common redox mechanistic pathways for MB and celastrol. That is, it is likely that celastrol exerts oxidative stress through attrition of reduced flavin cofactors associated with redox-active flavoenzymes such as glutathione reductase, thioredoxin reductase and others responsible for maintaining redox homeostasis in the malaria parasite. For the first time, the effect of celastrol against blood stage gametocytes was evaluated. In comparison with the gametocytocidal activities of known naphthoquinones, celastrol showed good activity against late stage gametocytes. The results provide substantial impetus for examining the antimalarial mechanism of action of celastrol. Thus, proposed future work will aim to more precisely define the redox activity of celastrol including a delineation of its actual effects on reduced flavin cofactors in relation to the behaviour of MB (cf. Figure 3) () and of naphthoquinones, as discussed in the Introduction.
For the antitumour activities, the key features that emerge here are the selectivities of artemiside and artemisone (SI > 170) toward the HepG2 cancer cell line with respect to LO2 normal cell line. Selectivity towards hepatocellular carcinoma elicited by artemisinins both in vitro and in vivo have been recorded previously (; Nandi et al., 2021) but here, an advantage is conferred by the relative lack of toxicity of artemisone especially with respect to the relatively neurotoxic DHA and its prodrugs artesunate and artemether (Schmeer et al., 2005; ; Vivas et al., 2007; Nagelschmitz et al., 2008; Wu et al., 2016; Watson et al., 2021). Artemiside that is active against the HepG2 carcinoma cell line as noted here, and against malaria and other apicomplexan parasites is metabolized to artemisone and other active metabolites in vivo that in essence greatly extends the half-life of active drug and enhances overall bioavailability (). Thus, the potential of artemiside to act as an antitumour agent requires further evaluation. In addition, we show here that drug interactions between each of artemiside and artemisone with celastrol are synergistic, thus supporting the strategy of combining the oxidant amino-artemisinin with the redox active celastrol. In this sense, the parallel in activities of the artemisone-celastrol combination with the artemisone - elesclomol-Cu as noted in the Introduction is apparent, and may involve a similar mechanistic pathway.
Overall, even though celastrol is so biologically active, its non-selectivity with respect to cytotoxicity towards normal cell lines is an issue, as has been noted on many occasions previously. Clearly, evaluation of selective formulation methods (Huang, T, et al., 2020; Shi et al., 2020; ; Wagh et al., 2021) or of relatively non-toxic derivatives (; ; ) must continue in order to develop celastrol as a potent and successful drug.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
The study involving the antimalarial activities was carried out according to the guidelines set out and approved by the Faculty of Health Sciences ethics committee (506/2018) and Natural and Agricultural Sciences Ethics Committee (180000094) at the University of Pretoria. All subjects gave written informed consent in accordance with the Declaration of Helsinki.
Author contributions
Conceptualization: RKH, PC, VW; methodologies: DC, L-MB. (malaria efficacy studies), YH, LY. (antitumour assays); compounds RKH, HW, PC; data curation, DC, L-MB, JN; project administration, RKH, PC, and VW; funding acquisition, RKH, PC, VW, L-MB; writing—original draft preparation, PC, RKH, JN; writing—review and editing, all authors; all authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the project of Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery from the Macau Science and Technology Development Fund (Project code: 001/2020/ALC), FDCT project code (0033/2019/AFJ) and the Foshan Medicine Dengfeng Project of China (2019–2021) to VW, Faculty research grant from Macau University Science and Technology (Project code: FRG-22-077-SP) to PC, the South African Medical Research Council (MRC) Flagship Project MALTB-Redox with funds from the National Treasury under its Economic Competitiveness and Support Package (UID MRC-RFA-UFSP-01–2013) (RKH), by the South African National Research Foundation (SA NRF) grants (UID 90682 and 98934) (RKH), the South African MRC Strategic Health Innovation Partnership (SHIP) grant, a South African MRC Collaborative Centre for Malaria Research grant (DC and L-MB), and the Department of Science and Innovation and SA NRF South African Research Chairs Initiative (SARChI) Grant (UID 84627, L-MB).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.988748/full#supplementary-material
References
1
AdjalleyS. H.JohnstonG. L.LiT.EastmanR. T.EklandE. H.EappenA. G.et al (2011). Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl. Acad. Sci. U. S. A.108, E1214–E1223. 10.1073/pnas.1112037108
2
AhenkorahS.CoertzenD.TongJ. X.FridiantoK.WittlinS.BirkholtzL. M.et al (2020). Antimalarial N(1), N(3)-dialkyldioxonaphthoimidazoliums: Synthesis, biological activity, and structure-activity relationships. ACS Med. Chem. Lett.11, 49–55. 10.1021/acsmedchemlett.9b00457
3
AkoachereM.BuchholzK.FischerE.BurhenneJ.HaefeliW. E.SchirmerR. H.et al (2005). In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob. Agents Chemother.49, 4592–4597. 10.1128/AAC.49.11.4592-4597.2005
4
AugustinY.StainesH. M.KrishnaS. (2020). Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing. Pharmacol. Ther.216, 107706. 10.1016/j.pharmthera.2020.107706
5
BassaniniI.ParapiniS.FerrandiE. E.GabrieleE.BasilicoN.TaramelliD.et al (2021). Design, synthesis and in vitro investigation of novel basic celastrol carboxamides as bio-inspired leishmanicidal agents endowed with inhibitory activity against leishmania Hsp90. Biomolecules11, 56. 10.3390/biom11010056
6
BridgfordJ. L.XieS. C.CobboldS. A.PasajeC. F. A.HerrmannS.YangT.et al (2018). Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat. Commun.9, 3801. 10.1038/s41467-018-06221-1
7
BuchholzK.SchirmerR. H.EubelJ. K.AkoachereM. B.DandekarT.BeckerK.et al (2008). Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother.52, 183–191. 10.1128/AAC.00773-07
8
ChenM.YangJ.LiL.HuY.LuX.SunR.et al (2020). Metabolomics reveals that cysteine metabolism plays a role in celastrol-induced mitochondrial apoptosis in HL-60 and NB-4 cells. Sci. Rep.10, 471. 10.1038/s41598-019-57312-y
9
ChenS. R.DaiY.ZhaoJ.LinL.WangY.WangY. (2018). A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii hook F. Front. Pharmacol.9, 104. 10.3389/fphar.2018.00104
10
CoertzenD.ReaderJ.Van Der WattM.NondabaS. H.GibhardL.WiesnerL.et al (2018). Artemisone and artemiside are potent panreactive antimalarial agents that also synergize redox imbalance in Plasmodium falciparum transmissible gametocyte stages. Antimicrob. Agents Chemother.62, e02214–17. 10.1128/AAC.02214-17
11
CoghiP.NgJ. P. L.KadiogluO.LawB. Y. K.QiuA. C.SaeedM. E. M.et al (2021). Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy. Eur. J. Med. Chem.224, 113676. 10.1016/j.ejmech.2021.113676
12
CuiL.SuX. Z. (2009). Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev. anti. Infect. Ther.7, 999–1013. 10.1586/eri.09.68
13
DasA. K. (2015). Anticancer effect of AntiMalarial artemisinin compounds. Ann. Med. Health Sci. Res.5, 93–102. 10.4103/2141-9248.153609
14
DwivediA.MazumderA.Du PlessisL.Du PreezJ. L.HaynesR. K.Du PlessisJ. (2015). In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine.11, 2041–2050. 10.1016/j.nano.2015.07.010
15
EastmanR. T.FidockD. A. (2009). Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol.7, 864–874. 10.1038/nrmicro2239
16
EfferthT. (2017). Cancer combination therapies with artemisinin-type drugs. Biochem. Pharmacol.139, 56–70. 10.1016/j.bcp.2017.03.019
17
EhrhardtK.DeregnaucourtC.GoetzA. A.TzanovaT.GalloV.AreseP.et al (2016). The redox cycler plasmodione is a fast-acting antimalarial lead compound with pronounced activity against sexual and early asexual blood-stage parasites. Antimicrob. Agents Chemother.60, 5146–5158. 10.1128/AAC.02975-15
18
FigueiredoJ. N.RäzB.SéquinU. (1998). Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J. Nat. Prod.61, 718–723. 10.1021/np9704157
19
FivelmanQ. L.AdaguI. S.WarhurstD. C. (2004). Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother.48, 4097–4102. 10.1128/AAC.48.11.4097-4102.2004
20
GiannangeloC.AndersonD.WangX.VennerstromJ. L.CharmanS. A.CreekD. J. (2019). Ozonide antimalarials alkylate heme in the malaria parasite Plasmodium falciparum. ACS Infect. Dis.5, 2076–2086. 10.1021/acsinfecdis.9b00257
21
GibhardL.CoertzenD.ReaderJ.Van Der WattM. E.BirkholtzL. M.WongH. N.et al (2021). The artemiside-artemisox-artemisone-M1 tetrad: Efficacies against blood stage P. Falciparum parasites, DMPK properties, and the case for artemiside. Pharmaceutics13, 2066. 10.3390/pharmaceutics13122066
22
GravettA. M.LiuW. M.KrishnaS.ChanW. C.HaynesR. K.WilsonN. L.et al (2011). In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother. Pharmacol.67, 569–577. 10.1007/s00280-010-1355-4
23
GreenshieldsA. L.FernandoW.HoskinD. W. (2019). The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp. Mol. Pathol.107, 10–22. 10.1016/j.yexmp.2019.01.006
24
GuoL.ZhangY.Al-JamalK. T. (2021). Recent progress in nanotechnology-based drug carriers for celastrol delivery. Biomater. Sci.9, 6355–6380. 10.1039/D1BM00639H
25
GuptaS.ThaparM. M.WernsdorferW. H.BjörkmanA. (2002). In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother 46. Antimicrob. Agents Chemother.46, 1510–1515. 10.1128/AAC.46.5.1510-1515.2002
26
HaynesR. K.ChanW. C.WongH. N.LiK. Y.WuW. K.FanK. M.et al (2010). Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: Relationship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem5, 1282–1299. 10.1002/cmdc.201000225
27
HaynesR. K.CheuK. W.ChanH. W.WongH. N.LiK. Y.TangM. M.et al (2012). Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model--a unifying proposal for drug action. ChemMedChem7, 2204–2226. 10.1002/cmdc.201200383
28
HaynesR. K.CheuK. W.N'daD.CoghiP.MontiD. (2013). Considerations on the mechanism of action of artemisinin antimalarials: Part 1--the 'carbon radical' and 'heme' hypotheses. Infect. Disord. Drug Targets13, 217–277. 10.2174/1871526513666131129155708
29
HaynesR. K.CheuK. W.TangM. M.ChenM. J.GuoZ. F.GuoZ. H.et al (2011). Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: Flavin reductase and the cofactor model exemplified. ChemMedChem6, 279–291. 10.1002/cmdc.201000508
30
HaynesR. K.FugmannB.StetterJ.RieckmannK.HeilmannH. D.ChanH. W.et al (2006). Artemisone--a highly active antimalarial drug of the artemisinin class. Angew. Chem. Int. Ed. Engl.45, 2082–2088. 10.1002/anie.200503071
31
HaynesR. K.HoW. Y.ChanH. W.FugmannB.StetterJ.CroftS. L.et al (2004). Highly antimalaria-active artemisinin derivatives: Biological activity does not correlate with chemical reactivity. Angew. Chem. Int. Ed. Engl.43, 1381–1385. 10.1002/anie.200352343
32
Hooft Van HuijsduijnenR.GuyR. K.ChibaleK.HaynesR. K.PeitzI.KelterG.et al (2013). Anticancer properties of distinct antimalarial drug classes. PLoS One8, e82962. 10.1371/journal.pone.0082962
33
HouJ.WangD.ZhangR.WangH. (2008). Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res.14, 5519–5530. 10.1158/1078-0432.CCR-08-0197
34
HuangT.WangY.ShenY.AoH.GuoY.HanM.et al (2020). Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo. Sci. Rep.10, 8851. 10.1038/s41598-020-65773-9
35
KianiB. H.KayaniW. K.KhayamA. U.DilshadE.IsmailH.MirzaB. (2020). Artemisinin and its derivatives: A promising cancer therapy. Mol. Biol. Rep.47, 6321–6336. 10.1007/s11033-020-05669-z
36
KlaićL.MorimotoR. I.SilvermanR. B. (2012). Celastrol analogues as inducers of the heat shock response. Design and synthesis of affinity probes for the identification of protein targets. ACS Chem. Biol.7, 928–937. 10.1021/cb200539u
37
KlotzL. O.HouX.JacobC. (2014). 1, 4-naphthoquinones: From oxidative damage to cellular and inter-cellular signaling. Molecules19, 14902–14918. 10.3390/molecules190914902
38
KoltaiT. (2021). Is artesunate the best partner of gemcitabine in pancreatic cancer?Eur. J. Clin. Med.3, 1–12. 10.24018/clinicmed.2022.3.3.202
39
Konstat-KorzennyE.Ascencio-AragónJ. A.Niezen-LugoS.Vázquez-LópezR. (2018). Artemisinin and its synthetic derivatives as a possible therapy for cancer. Med. Sci.6, E19. 10.3390/medsci6010019
40
KuceraH. R.LivingstoneM.MoscosoC. G.GaikwadN. W. (2013). Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides. Free Radic. Res.47, 1016–1026. 10.3109/10715762.2013.847527
41
KumarM. S.YadavT. T.KhairR. R.PetersG. J.YergeriM. C. (2019). Combination therapies of artemisinin and its derivatives as a viable approach for future cancer treatment. Curr. Pharm. Des.25, 3323–3338. 10.2174/1381612825666190902155957
42
LanfranchiD. A.BelorgeyD.MüllerT.VezinH.LanzerM.Davioud-CharvetE. (2012). Exploring the trifluoromenadione core as a template to design antimalarial redox-active agents interacting with glutathione reductase. Org. Biomol. Chem.10, 4795–4806. 10.1039/c2ob25229e
43
LiG.LiY.LiZ.ZengM. (2017). Artemisinin-based and other antimalarials: Detailed account of studies by Chinese scientists who discovered and developed them. Amsterdam, Netherlands: Elsevier.
44
LiJ. J.YanY. Y.SunH. M.LiuY.SuC. Y.ChenH. B.et al (2019). Anti-cancer effects of pristimerin and the mechanisms: A critical review. Front. Pharmacol.10, 746. 10.3389/fphar.2019.00746
45
LuY.LiuY.ZhouJ.LiD.GaoW. (2021). Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone-methide triterpenoid celastrol. Med. Res. Rev.41, 1022–1060. 10.1002/med.21751
46
Mairet-KhedimM.LeangR.MarmaiC.KhimN.KimS.KeS.et al (2021). Clinical and in vitro resistance of Plasmodium falciparum to artesunate-amodiaquine in Cambodia. Clin. Infect. Dis.73, 406–413. 10.1093/cid/ciaa628
47
MancusoR. I.FoglioM. A.Olalla SaadS. T. (2021). Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemother. Pharmacol.87, 1–22. 10.1007/s00280-020-04170-5
48
Martín Del CampoJ. S.VogelaarN.TolaniK.KizjakinaK.HarichK.SobradoP. (2016). Inhibition of the flavin-dependent monooxygenase siderophore A (SidA) blocks siderophore biosynthesis and Aspergillus fumigatus growth. ACS Chem. Biol.11, 3035–3042. 10.1021/acschembio.6b00666
49
MbengueA.BhattacharjeeS.PandharkarT.LiuH.EstiuG.StahelinR. V.et al (2015). A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature520, 683–687. 10.1038/nature14412
50
MoreiraH.SzyjkaA.PaliszkiewiczK.BargE. (2019). Prooxidative activity of celastrol induces apoptosis, DNA damage, and cell cycle arrest in drug-resistant human colon cancer cells. Oxid. Med. Cell. Longev.2019, 6793957. 10.1155/2019/6793957
51
NagelschmitzJ.VoithB.WensingG.RoemerA.FugmannB.HaynesR. K.et al (2008). First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother.52, 3085–3091. 10.1128/AAC.01585-07
52
NandiD.CheemaP. S.SingalA.BhartiH.NagA. (2021). Artemisinin mediates its tumor-suppressive activity in hepatocellular carcinoma through targeted inhibition of FoxM1. Front. Oncol.11, 751271. 10.3389/fonc.2021.751271
53
NgJ. P. L.TiwariM. K.NasimA. A.ZhangR. L.QuY.SharmaR.et al (2022)., 15. Pharmaceuticals (Basel, 360. 10.3390/ph15030360Biological evaluation in resistant cancer cells and study of mechanism of action of arylvinyl-1, 2, 4-trioxanesPharmaceuticals
54
OhrtC.WillingmyreG. D.LeeP.KnirschC.MilhousW. (2002). Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother.46, 2518–2524. 10.1128/AAC.46.8.2518-2524.2002
55
OujiM.AugereauJ. M.PaloqueL.Benoit-VicalF. (2018). Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of damocles in the path toward malaria elimination. Parasite25, 24. 10.1051/parasite/2018021
56
PengB.WangY.SongY. T.ZhangX.CaoF. F.XuL. M.et al (2019). “Therapeutic effects and related molecular mechanisms of celastrol, a triterpenoid natural compound and novel HSP90 inhibitor extracted from plants of the celastraceae family,” in Heat shock protein 90 in human diseases and disorders. Heat shock proteins. Editors AseaA.KaurP. (Cham: Springer), Vol. 19. 10.1007/978-3-030-23158-3_20
57
PhyoA. P.Von SeidleinL. (2017). Challenges to replace ACT as first-line drug. Malar. J.16, 296. 10.1186/s12936-017-1942-5
58
QinG.WuL.LiuH.PangY.ZhaoC.WuS.et al (2015). Artesunate induces apoptosis via a ROS-independent and Bax-mediated intrinsic pathway in HepG2 cells. Exp. Cell Res.336, 308–317. 10.1016/j.yexcr.2015.07.004
59
QuadrosH. C.SilvaM. C. B.MoreiraD. R. M. (2022). The role of the iron protoporphyrins heme and hematin in the antimalarial activity of endoperoxide drugs. Pharm. (Basel)15, 60. 10.3390/ph15010060
60
ReaderJ.BothaM.TheronA.LauterbachS. B.RossouwC.EngelbrechtD.et al (2015). Nowhere to hide: Interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malar. J.14, 213. 10.1186/s12936-015-0718-z
61
ReaderJ.Van Der WattM.BirkholtzL. M. (2022). Streamlined and robust stage-specific profiling of gametocytocidal compounds against Plasmodium falciparum. Front. Cell. Infect. Microbiol.589, 926460. 10.3389/fcimb.2022.926460
62
RocamoraF.ZhuL.LiongK. Y.DondorpA.MiottoO.MokS.et al (2018). Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLoS Pathog.14, e1006930. 10.1371/journal.ppat.1006930
63
SchmeerK.BreyerM.HuckeK.GaefkeD.KernA.SchmuckG. (2005) “Artemifone, a new anti-malarial artemisinin derivative: Metabolism in vitro in liver microsomes and hepatocyte sandwich cultures of different species including man,” in XVI International Congress for Tropical Medicine and Malaria: Medicine And Health In The Tropics, Marseille, France, 11-15 September 2005.144
64
ShiJ.LiJ.XuZ.ChenL.LuoR.ZhangC.et al (2020). Celastrol: A review of useful strategies overcoming its limitation in anticancer application. Front. Pharmacol.11, 558741. 10.3389/fphar.2020.558741
65
SidorovP.DestaI.ChesséM.HorvathD.MarcouG.VarnekA.et al (2016). Redox polypharmacology as an emerging strategy to combat malarial parasites. ChemMedChem11, 1339–1351. 10.1002/cmdc.201600009
66
SiriwardanaA.IyengarK.RoepeP. D. (2016). Endoperoxide drug cross-resistance patterns for Plasmodium falciparum exhibiting an artemisinin delayed-clearance phenotype. Antimicrob. Agents Chemother.60, 6952–6956. 10.1128/AAC.00857-16
67
SmilksteinM.SriwilaijaroenN.KellyJ. X.WilairatP.RiscoeM. (2004). Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother.48, 1803–1806. 10.1128/AAC.48.5.1803-1806.2004
68
TanakaT. Q.GuiguemdeW. A.BarnettD. S.MaronM. I.MinJ.ConnellyM. C.et al (2015). Potent Plasmodium falciparum gametocytocidal activity of diaminonaphthoquinones, lead antimalarial chemotypes identified in an antimalarial compound screen. Antimicrob. Agents Chemother.59, 1389–1397. 10.1128/AAC.01930-13
69
VerlindenB. K.NiemandJ.SnymanJ.SharmaS. K.BeattieR. J.WosterP. M.et al (2011). Discovery of novel alkylated (bis)urea and (bis)thiourea polyamine analogues with potent antimalarial activities. J. Med. Chem.54, 6624–6633. 10.1021/jm200463z
70
VivasL.RattrayL.StewartL. B.RobinsonB. L.FugmannB.HaynesR. K.et al (2007). Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J. Antimicrob. Chemother.59, 658–665. 10.1093/jac/dkl563
71
WaghP. R.DesaiP.PrabhuS.WangJ. (2021). Nanotechnology-based celastrol formulations and their therapeutic applications. Front. Pharmacol.12, 673209. 10.3389/fphar.2021.673209
72
WatsonD. J.LaingL.GibhardL.WongH. N.HaynesR. K.WiesnerL. (2021). Toward new transmission-blocking combination therapies: Pharmacokinetics of 10-amino-artemisinins and 11-aza-artemisinin and comparison with dihydroartemisinin and artemether. Antimicrob. Agents Chemother.65, e0099021. 10.1128/AAC.00990-21
73
WellemsT. E.SáJ. M.SuX. Z.ConnellyS. V.EllisA. C. (2020). Artemisinin resistance': Something new or old? Something of a misnomer?Trends Parasitol.36, 735–744. 10.1016/j.pt.2020.05.013
74
WellsT. N.AlonsoP. L.GutteridgeW. E. (2009). New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov.8, 879–891. 10.1038/nrd2972
75
WongH. N.LewiesA.HaighM.ViljoenJ. M.WentzelJ. F.HaynesR. K.et al (2020). Anti-melanoma activities of artemisone and prenylated amino-artemisinins in combination with known anticancer drugs. Front. Pharmacol.11, 558894. 10.3389/fphar.2020.558894
76
WongH. N.Padín-IrizarryV.Van Der WattM. E.ReaderJ.LiebenbergW.WiesnerL.et al (2019). Optimal 10-aminoartemisinins with potent transmission-blocking capabilities for new artemisinin combination therapies-activities against blood stage P. Falciparum including PfKI3 C580Y mutants and liver stage P. Berghei parasites. Front. Chem.7, 901. 10.3389/fchem.2019.00901
77
WoodrowC. J.WhiteN. J. (2017). The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol. Rev.41, 34–48. 10.1093/femsre/fuw037
78
World Health Organisation, (2021) World Health organisation. World Malaria Report 2021; ISBN 978-92-4-004049-6 (electronic version).
79
WuY.ParapiniS.WilliamsI. D.MisianoP.WongH. N.TaramelliD.et al (2018). Facile preparation of N-glycosylated 10-piperazinyl artemisinin derivatives and evaluation of their antimalarial and cytotoxic activities. Molecules23, 1713. 10.3390/molecules23071713
80
WuY.WuR. W.CheuK. W.WilliamsI. D.KrishnaS.SlavicK.et al (2016). Methylene homologues of artemisone: An unexpected structure-activity relationship and a possible implication for the design of C10-substituted artemisinins. ChemMedChem11, 1469–1479. 10.1002/cmdc.201600011
81
YounsM.AskouraM.AbbasH. A.AttiaG. H.KhayyatA. N.GodaR. M.et al (2021). Celastrol modulates multiple signaling pathways to inhibit proliferation of pancreatic cancer via DDIT3 and ATF3 up-regulation and RRM2 and MCM4 down-regulation. Onco. Targets. Ther.14, 3849–3860. 10.2147/OTT.S313933
Summary
Keywords
celastrol, redox drug, artemisinin, artemisone, synergism, malaria, cancer
Citation
Ng JPL, Han Y, Yang LJ, Birkholtz L-M, Coertzen D, Wong HN, Haynes RK, Coghi P and Wong VKW (2022) Antimalarial and antitumour activities of the steroidal quinone-methide celastrol and its combinations with artemiside, artemisone and methylene blue. Front. Pharmacol. 13:988748. doi: 10.3389/fphar.2022.988748
Received
07 July 2022
Accepted
08 August 2022
Published
02 September 2022
Volume
13 - 2022
Edited by
Carmenza Spadafora, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Panama
Reviewed by
Guozheng Huang, Anhui University of Technology, China
Kevin Spelman, MCPHS University, United States
Updates
Copyright
© 2022 Ng, Han, Yang, Birkholtz, Coertzen, Wong, Haynes, Coghi and Wong.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Richard K. Haynes, haynes@ust.hk Paolo Coghi, coghips@must.edu.mo Vincent Kam Wai Wong, bowaiwong@gmail.com
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.